Kane Biotech Inc (KNE) - Total Liabilities
Based on the latest financial reports, Kane Biotech Inc (KNE) has total liabilities worth CA$3.53 Million CAD (≈ $2.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Kane Biotech Inc cash conversion from operations to assess how effectively this company generates cash.
Kane Biotech Inc - Total Liabilities Trend (2003–2024)
This chart illustrates how Kane Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. See what is Kane Biotech Inc's book value for net asset value and shareholders' equity analysis.
Kane Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Kane Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Altur Slatina
RO:ALT
|
Romania | RON44.51 Million |
|
Kuke Music Holding Ltd
NYSE:KUKE
|
USA | $223.50 Million |
|
Beston Global Food Company Ltd
AU:BFC
|
Australia | AU$94.98 Million |
|
Gold Basin Resources Corp
V:GXX
|
Canada | CA$1.89 Million |
|
ABM International Limited
NSE:ABMINTLLTD
|
India | Rs-135.28 Million |
|
ADDvise Group AB A
ST:ADDV-A
|
Sweden | Skr1.81 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Kane Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Kane Biotech Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kane Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kane Biotech Inc (2003–2024)
The table below shows the annual total liabilities of Kane Biotech Inc from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$4.12 Million ≈ $2.98 Million |
-70.74% |
| 2023-12-31 | CA$14.09 Million ≈ $10.19 Million |
+44.40% |
| 2022-12-31 | CA$9.76 Million ≈ $7.06 Million |
+26.70% |
| 2021-12-31 | CA$7.70 Million ≈ $5.57 Million |
+94.43% |
| 2020-12-31 | CA$3.96 Million ≈ $2.87 Million |
+106.42% |
| 2019-12-31 | CA$1.92 Million ≈ $1.39 Million |
-24.48% |
| 2018-12-31 | CA$2.54 Million ≈ $1.84 Million |
+285.53% |
| 2017-12-31 | CA$659.03K ≈ $476.74K |
-15.91% |
| 2016-12-31 | CA$783.72K ≈ $566.93K |
+13.11% |
| 2015-12-31 | CA$692.86K ≈ $501.21K |
+4.27% |
| 2014-12-31 | CA$664.51K ≈ $480.70K |
+10.69% |
| 2013-12-31 | CA$600.31K ≈ $434.26K |
+239.68% |
| 2012-12-31 | CA$176.73K ≈ $127.84K |
+90.59% |
| 2011-12-31 | CA$92.72K ≈ $67.08K |
+2.18% |
| 2010-12-31 | CA$90.75K ≈ $65.65K |
+32.25% |
| 2009-12-31 | CA$68.62K ≈ $49.64K |
-13.76% |
| 2008-12-31 | CA$79.56K ≈ $57.55K |
-9.44% |
| 2007-12-31 | CA$87.86K ≈ $63.56K |
-5.36% |
| 2006-12-31 | CA$92.83K ≈ $67.16K |
-31.04% |
| 2005-12-31 | CA$134.62K ≈ $97.38K |
+35.00% |
| 2004-12-31 | CA$99.72K ≈ $72.14K |
+74.88% |
| 2003-12-31 | CA$57.02K ≈ $41.25K |
-- |
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the … Read more